news & events
portfolio news
19.11.20
CorWave Secures a €500,000 Grant From the Paris Region for Its Industrial Facilities
18.11.20
Vivet Therapeutics and Pfizer Inc. Announce FDA Authorization to Proceed with GATEWAY, the Phase 1/2 Study for VTX-801, Vivet’s Investigational Gene Therapy for Wilson Disease
16.11.20
Minoryx’s preclinical data for leriglitazone in Friedreich’s Ataxia published in Neurobiology of Disease Journal
12.11.20
AM-Pharma Announces Enrollment of the First Patient in REVIVAL Phase III Pivotal Trial in Patients with Sepsis-Associated Acute Kidney Injury
12.11.20
Galecto Announces Pricing of Initial Public Offering
30.10.20
European Investment Bank provides Minoryx with up to €25 million to support development of breakthrough therapies in orphan neurodegenerative diseases
29.10.20
SparingVision Strengthens Management Team
27.10.20
Kala Pharmaceuticals Announces FDA Approval of EYSUVIS™ for the Short-Term Treatment of the Signs and Symptoms of Dry Eye Disease
21.10.20
SparingVision Raises €44.5 Million and Appoints Stéphane Boissel as Chief Executive Officer
12.10.20
Sanifit to Present New Data on SNF472 for Vascular Calcification at the American Society of Nephrology Kidney Week 2020
